A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: A phase II study

G. Frasci, G. Nicolella, P. Comella, I. Carreca, G. DeCataldis, D. Muci, C. Brunetti, M. Natale, F. Piantedosi, A. Russo, S. Palmeri, G. Comella, N. Panza

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.

Original languageEnglish
Pages (from-to)1166-1171
Number of pages6
JournalBritish Journal of Cancer
Volume84
Issue number9
DOIs
Publication statusPublished - May 4 2001

Fingerprint

Topotecan
Small Cell Lung Carcinoma
Granulocyte Colony-Stimulating Factor
Paresthesia
Poisons
Paclitaxel
Neutropenia
Thrombocytopenia
Cisplatin
Disease-Free Survival
Fatigue
TP protocol
Diarrhea
Sepsis
Survival

Keywords

  • Paclitaxel
  • Small cell lung cancer
  • Topotecan
  • Weekly chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer : A phase II study. / Frasci, G.; Nicolella, G.; Comella, P.; Carreca, I.; DeCataldis, G.; Muci, D.; Brunetti, C.; Natale, M.; Piantedosi, F.; Russo, A.; Palmeri, S.; Comella, G.; Panza, N.

In: British Journal of Cancer, Vol. 84, No. 9, 04.05.2001, p. 1166-1171.

Research output: Contribution to journalArticle

Frasci, G, Nicolella, G, Comella, P, Carreca, I, DeCataldis, G, Muci, D, Brunetti, C, Natale, M, Piantedosi, F, Russo, A, Palmeri, S, Comella, G & Panza, N 2001, 'A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: A phase II study', British Journal of Cancer, vol. 84, no. 9, pp. 1166-1171. https://doi.org/10.1054/bjoc.2001.1741
Frasci, G. ; Nicolella, G. ; Comella, P. ; Carreca, I. ; DeCataldis, G. ; Muci, D. ; Brunetti, C. ; Natale, M. ; Piantedosi, F. ; Russo, A. ; Palmeri, S. ; Comella, G. ; Panza, N. / A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer : A phase II study. In: British Journal of Cancer. 2001 ; Vol. 84, No. 9. pp. 1166-1171.
@article{971a6c41a02d41cbb061267e7e36a232,
title = "A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: A phase II study",
abstract = "The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22{\%}) and 22 partial responses (59{\%}) were recorded, giving an 81{\%} [95{\%} Cl = 65-92{\%}] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55{\%} and 21{\%}, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.",
keywords = "Paclitaxel, Small cell lung cancer, Topotecan, Weekly chemotherapy",
author = "G. Frasci and G. Nicolella and P. Comella and I. Carreca and G. DeCataldis and D. Muci and C. Brunetti and M. Natale and F. Piantedosi and A. Russo and S. Palmeri and G. Comella and N. Panza",
year = "2001",
month = "5",
day = "4",
doi = "10.1054/bjoc.2001.1741",
language = "English",
volume = "84",
pages = "1166--1171",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer

T2 - A phase II study

AU - Frasci, G.

AU - Nicolella, G.

AU - Comella, P.

AU - Carreca, I.

AU - DeCataldis, G.

AU - Muci, D.

AU - Brunetti, C.

AU - Natale, M.

AU - Piantedosi, F.

AU - Russo, A.

AU - Palmeri, S.

AU - Comella, G.

AU - Panza, N.

PY - 2001/5/4

Y1 - 2001/5/4

N2 - The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.

AB - The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.

KW - Paclitaxel

KW - Small cell lung cancer

KW - Topotecan

KW - Weekly chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=17844406865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844406865&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2001.1741

DO - 10.1054/bjoc.2001.1741

M3 - Article

C2 - 11336465

AN - SCOPUS:17844406865

VL - 84

SP - 1166

EP - 1171

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -